Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics”
Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin.
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for the Advancement of Science
2021
|
| _version_ | 1797107890329223168 |
|---|---|
| author | Bovijn, J Krebs, K Chen, C-Y Boxall, R Censin, JC Ferreira, T Pulit, SL Glastonbury, CA Laber, S Millwood, IY Lin, K Li, L Chen, Z Milani, L Smith, GD Walters, RG Mägi, R Neale, BM Lindgren, CM Holmes, MV |
| author_facet | Bovijn, J Krebs, K Chen, C-Y Boxall, R Censin, JC Ferreira, T Pulit, SL Glastonbury, CA Laber, S Millwood, IY Lin, K Li, L Chen, Z Milani, L Smith, GD Walters, RG Mägi, R Neale, BM Lindgren, CM Holmes, MV |
| author_sort | Bovijn, J |
| collection | OXFORD |
| description | Triangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin. |
| first_indexed | 2024-03-07T07:21:59Z |
| format | Journal article |
| id | oxford-uuid:e4cf650a-7d29-4448-96f6-b41ab3b5a503 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:21:59Z |
| publishDate | 2021 |
| publisher | American Association for the Advancement of Science |
| record_format | dspace |
| spelling | oxford-uuid:e4cf650a-7d29-4448-96f6-b41ab3b5a5032022-10-13T13:28:18ZResponse to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics”Journal articlehttp://purl.org/coar/resource_type/c_6501uuid:e4cf650a-7d29-4448-96f6-b41ab3b5a503EnglishSymplectic ElementsAmerican Association for the Advancement of Science2021Bovijn, JKrebs, KChen, C-YBoxall, RCensin, JCFerreira, TPulit, SLGlastonbury, CALaber, SMillwood, IYLin, KLi, LChen, ZMilani, LSmith, GDWalters, RGMägi, RNeale, BMLindgren, CMHolmes, MVTriangulation of evidence from clinical trials and human genetics suggests a potential excess risk of cardiovascular disease events arising from therapeutic inhibition of sclerostin. |
| spellingShingle | Bovijn, J Krebs, K Chen, C-Y Boxall, R Censin, JC Ferreira, T Pulit, SL Glastonbury, CA Laber, S Millwood, IY Lin, K Li, L Chen, Z Milani, L Smith, GD Walters, RG Mägi, R Neale, BM Lindgren, CM Holmes, MV Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics” |
| title | Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics” |
| title_full | Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics” |
| title_fullStr | Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics” |
| title_full_unstemmed | Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics” |
| title_short | Response to comment on “Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics” |
| title_sort | response to comment on evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta analysis of clinical trials and human genetics |
| work_keys_str_mv | AT bovijnj responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT krebsk responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT chency responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT boxallr responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT censinjc responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT ferreirat responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT pulitsl responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT glastonburyca responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT labers responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT millwoodiy responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT link responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT lil responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT chenz responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT milanil responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT smithgd responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT waltersrg responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT magir responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT nealebm responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT lindgrencm responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics AT holmesmv responsetocommentonevaluatingthecardiovascularsafetyofsclerostininhibitionusingevidencefrommetaanalysisofclinicaltrialsandhumangenetics |